Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PTCT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPTC Therapeutics adds Morgan Stanley healthcare banking veteran Jessica Chutter to board
Filed March 25, 2026 · Period ending March 24, 2026 · ~1 min read
Key Changes
-
medium
Jessica Chutter, former Vice Chair of Healthcare Investment Banking at Morgan Stanley with 40+ years of experience, appointed to board effective March 24, 2026 as Class I director with term expiring at 2026 annual meeting.
Item 5.02 verify on EDGAR → -
low
Chutter received initial equity grant of 3,475 stock options (vesting monthly over 36 months) and 4,000 RSUs (vesting annually over 3 years), plus pro-rated 2026 annual grant of 2,896 options and 3,333 RSUs.
Item 5.02 verify on EDGAR → -
low
New director will receive standard $50,000 annual cash retainer plus travel expense reimbursement, consistent with existing outside director compensation policy.
Item 5.02 verify on EDGAR →
Summary
PTC Therapeutics expanded its board by appointing Jessica Chutter, a seasoned healthcare investment banking executive with over four decades at Morgan Stanley, where she most recently served as Vice Chair of Healthcare Investment Banking and Chair of Biotechnology Investment Banking. The appointment fills a board vacancy and brings deep capital markets and biotech sector expertise to the company's governance.
For retail investors, this is a routine but positive governance move. Chutter's extensive background in healthcare finance and biotechnology could prove valuable as PTC navigates capital allocation decisions, potential partnerships, or strategic transactions. Her appointment suggests the board is strengthening its financial and industry expertise.
Watch for Chutter's committee assignments at the upcoming 2026 annual meeting, as her placement on audit, compensation, or strategic committees would signal where the board sees her expertise adding most value. Her short initial term (expiring at the 2026 annual meeting) is standard for mid-year appointments and shareholders will vote on her continued service later this year.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
In connection with Ms. Chutter’s appointment to the Board, she will be entitled to compensation in accordance with the Company’s outside director compensation policy, under which each non-employee director receives a base annual retainer of $50,000 per year for service as a Board member.
Ms. Chutter will receive the standard non-employee director compensation of $50,000 per year base retainer, plus reimbursement for reasonable travel and meeting expenses. This is consistent with the company's existing outside director compensation policy.
Added in current filing · verify on EDGAR →
the Company granted Ms. Chutter, pursuant to the Company’s Amended and Restated 2013 Long-Term Incentive Plan, (i) an “initial director equity grant” consisting of 3,475 stock options to purchase shares of the Company’s common stock, which vest equally on a monthly basis over 36 months beginning on the one month anniversary of the grant date and 4,000 restricted stock units, which shares underlying such restricted stock units vest in three equal annual installments commencing on March 24, 2027, and (ii) an “annual director equity grant”, pro-rated for the remainder of 2026, consisting of 2,896 stock options to purchase shares of the Company’s common stock, which vest in ten equal monthly installments commencing on April 2, 2026, and 3,333 restricted stock units, with 1,000 shares underlying such restricted stock units vesting on June 2, 2026, and the remaining 2,333 shares vesting on January 2, 2027.
Ms. Chutter received two equity grants: an initial director grant of 3,475 stock options (vesting monthly over 36 months) and 4,000 RSUs (vesting annually over 3 years starting March 2027), plus a pro-rated 2026 annual grant of 2,896 stock options (vesting monthly over 10 months) and 3,333 RSUs (1,000 vesting June 2026, 2,333 vesting January 2027). These grants follow the company's standard outside director equity compensation policy.
Event · Item 7.01 — Regulation FD Disclosure
PTC Therapeutics announced the appointment of Ms. Chutter via press release on March 25, 2026.
Added in current filing · verify on EDGAR →
On March 25, 2026, the Company issued a press release in which it announced the appointment of Ms. Chutter described above.
PTC Therapeutics disclosed the appointment of Ms. Chutter through a press release. The 8-K references this appointment but does not provide details about the role, responsibilities, or background of Ms. Chutter within the filing body itself. The full details are contained in the attached press release (Exhibit 99.1), which is not included in the provided text.
Event · Item 9.01 — Financial Statements and Exhibits
PTC Therapeutics filed an 8-K attaching a press release dated March 25, 2026; no material event details disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press Release, dated March 25, 2026 issued by PTC Therapeutics, Inc.
The 8-K references an attached press release dated March 25, 2026. The filing body provides no details about the content or subject matter of the press release, making it impossible to assess materiality from this document alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify